Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2169/naika.103.188 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-World Safety, Tolerability and Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Final Report of Post-marketing Surveillance in Japan.
Adv Ther
December 2024
Professor Emeritus, Tohoku University, Sendai, Japan.
Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrotic interstitial pneumonia, which is characterised by progressive worsening of dyspnoea and lung function. Nintedanib treatment is recommended to slow IPF disease progression. The aim of this post-marketing surveillance (PMS) study was to evaluate the safety and effectiveness of nintedanib over 24 months in patients with IPF in a real-world setting in Japan.
View Article and Find Full Text PDFReal-world status of multimodal treatment of Stage IIIA-N2 non-small cell lung cancer in Japan: Results from the SOLUTION study, a non-interventional, multicenter cohort study.
Lung Cancer
November 2024
Department of Thoracic Surgery, National Cancer Center Hospital East, Chiba, Japan. Electronic address:
Objectives: There is limited consensus on resectability criteria for Stage IIIA-N2 non-small cell lung cancer (NSCLC). We examined the patient characteristics, N2 status, treatment decisions, and clinical outcomes according to the treatment modality for Stage IIIA-N2 NSCLC in Japan.
Materials And Methods: Patients with Stage IIIA-N2 NSCLC in Japan were consecutively registered in the SOLUTION study between 2013 and 2014.
A Case of Fibrolamellar Hepatocellular Carcinoma in Which Tumor Control Was Achieved by Re-Administering Atezolizumab and Bevacizumab.
Cancer Rep (Hoboken)
December 2024
Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
Background: Fibrolamellar hepatocellular carcinoma (FL-HCC) clinically occurs in young people aged 20-30 years, who often have a normal liver background. We propose a treatment for such cases in which a combination therapy of atezolizumab and bevacizumab is followed by sandwiching radiation therapy to release tumor antigens and then re-administering the combination therapy of atezolizumab and bevacizumab (ABC conversion therapy).
Case: The patient is a 15-year-old girl.
Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study.
Lung Cancer
December 2024
Internal Medicine III, Wakayama Medical University, Wakayama, Japan.
Article Synopsis
- The study investigates long-term outcomes of chemoimmunotherapy for extensive-stage small-cell lung cancer (ES-SCLC) using a large cohort of patients over a minimum follow-up period of 3 years.
- Most participants were trial-eligible, with significantly better overall survival rates compared to those who were not, highlighting the impact of eligibility criteria on treatment effectiveness.
- The results underscore the practical implications of long-term outcomes in real-world settings, aiding clinical decisions for managing ES-SCLC patients.
Post-discharge changes in nutritional status predict prognosis in patients with acute decompensated HFpEF from the PURSUIT-HFpEF Registry.
Heart Vessels
December 2024
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.
Article Synopsis
- Undernutrition has a negative impact on patients with heart failure and preserved ejection fraction (HFpEF), affecting their long-term prognosis after discharge.
- A study categorized 547 HFpEF patients based on their nutritional status at discharge and one year later, identifying those who normalized or worsened in their nutritional scores.
- The findings revealed that worsening nutritional scores increased the risk of all-cause mortality or readmission, while improving scores were linked to better outcomes, with certain predictors identified for changes in nutritional status.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!